• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小RNA-93通过直接抑制PTEN和CDKN1A激活肝细胞癌中的c-Met/PI3K/Akt信号通路活性。

MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.

作者信息

Ohta Katsuya, Hoshino Hiromitsu, Wang Jinhua, Ono Shigeshi, Iida Yuuki, Hata Keisuke, Huang Sharon K, Colquhoun Steven, Hoon Dave S B

机构信息

Department of Molecular Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.

Liver Disease and Transplant Center, Cedars-Sinai Medical Center, Beverly Hills, CA, USA.

出版信息

Oncotarget. 2015 Feb 20;6(5):3211-24. doi: 10.18632/oncotarget.3085.

DOI:10.18632/oncotarget.3085
PMID:25633810
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4413648/
Abstract

To assess the role of microRNAs (miR) in hepatocellular carcinoma (HCC), we performed comprehensive microRNA expression profiling using HCC cell lines and identified miR-93 as a novel target associated with HCC. We further verified miR-93 expression levels in advanced HCC tumors (n=47) by a direct PCR assay and found that elevated miR-93 expression level is significantly correlated with poor prognosis. Elevated miR-93 expression significantly stimulated in vitro cell proliferation, migration and invasion, and additionally inhibited apoptosis. We confirmed that miR-93 directly bound with the 3' untranslated regions of the tumor-suppressor genes PTEN and CDKN1A, respectively,and inhibited their expression. As a result of this inhibition, the c-Met/PI3K/Akt pathway activity was enhanced. IHC analysis of HCC tumors showed significant correlation between c-Met protein expression levels and miR-93 expression levels. Knockdown of c-Met inhibited the activation of the c-Met/PI3K/Akt pathway regardless of hepatocyte growth factor (HGF) treatment, and furthermore reduced the expression of miR-93 in these HCC cells. miR-93 also rendered cells to be more sensitive to sorafenib and tivantinib treatment. We concluded that miR-93 stimulated cell proliferation, migration, and invasion through the oncogenic c-Met/PI3K/Akt pathway and also inhibited apoptosis by directly inhibiting PTEN and CDKN1A expression in human HCC.

摘要

为了评估微小RNA(miR)在肝细胞癌(HCC)中的作用,我们利用肝癌细胞系进行了全面的微小RNA表达谱分析,并鉴定出miR-93是一种与肝癌相关的新靶点。我们通过直接PCR检测进一步验证了晚期肝癌肿瘤(n = 47)中miR-93的表达水平,发现miR-93表达水平升高与预后不良显著相关。miR-93表达升高显著促进体外细胞增殖、迁移和侵袭,并抑制细胞凋亡。我们证实miR-93分别直接与肿瘤抑制基因PTEN和CDKN1A的3'非翻译区结合,并抑制它们的表达。这种抑制作用导致c-Met/PI3K/Akt信号通路活性增强。肝癌肿瘤的免疫组化分析显示c-Met蛋白表达水平与miR-93表达水平之间存在显著相关性。敲低c-Met可抑制c-Met/PI3K/Akt信号通路的激活,而与肝细胞生长因子(HGF)处理无关,并且进一步降低了这些肝癌细胞中miR-93的表达。miR-93还使细胞对索拉非尼和替凡替尼治疗更敏感。我们得出结论,miR-93通过致癌性c-Met/PI3K/Akt信号通路刺激细胞增殖、迁移和侵袭,并通过直接抑制人肝癌中PTEN和CDKN1A的表达来抑制细胞凋亡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/5332b1fb51e9/oncotarget-06-3211-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/9fb7cac037dc/oncotarget-06-3211-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/04da745369b5/oncotarget-06-3211-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/c59e7955e9c8/oncotarget-06-3211-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/7f535f5fd442/oncotarget-06-3211-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/44efba2ab110/oncotarget-06-3211-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/8b2a1632f391/oncotarget-06-3211-g006a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/5332b1fb51e9/oncotarget-06-3211-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/9fb7cac037dc/oncotarget-06-3211-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/04da745369b5/oncotarget-06-3211-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/c59e7955e9c8/oncotarget-06-3211-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/7f535f5fd442/oncotarget-06-3211-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/44efba2ab110/oncotarget-06-3211-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/8b2a1632f391/oncotarget-06-3211-g006a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d25/4413648/5332b1fb51e9/oncotarget-06-3211-g007.jpg

相似文献

1
MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.微小RNA-93通过直接抑制PTEN和CDKN1A激活肝细胞癌中的c-Met/PI3K/Akt信号通路活性。
Oncotarget. 2015 Feb 20;6(5):3211-24. doi: 10.18632/oncotarget.3085.
2
MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.微小RNA-21通过PTEN/蛋白激酶B信号通路抑制自噬,从而介导肝癌细胞对索拉非尼的耐药性。
Oncotarget. 2015 Oct 6;6(30):28867-81. doi: 10.18632/oncotarget.4814.
3
MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.微小RNA-155-5p通过PI3K/Akt信号通路抑制PTEN从而促进肝细胞癌进展。
Cancer Sci. 2017 Apr;108(4):620-631. doi: 10.1111/cas.13177. Epub 2017 Apr 19.
4
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2.在肝细胞癌中,miR-519d 受 p53 和 DNA 低甲基化的上调,并靶向 CDKN1A/p21、PTEN、AKT3 和 TIMP2。
J Pathol. 2012 Jul;227(3):275-85. doi: 10.1002/path.3995. Epub 2012 Apr 18.
5
MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1.miR-128-3p 过表达通过调控 DJ-1 使肝癌细胞对索拉非尼诱导的细胞凋亡敏感。
Eur Rev Med Pharmacol Sci. 2018 Oct;22(20):6667-6677. doi: 10.26355/eurrev_201810_16143.
6
Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.在肝癌细胞对索拉非尼产生获得性耐药后,双重抑制Akt和c-Met作为二线治疗方案。
Mol Oncol. 2017 Mar;11(3):320-334. doi: 10.1002/1878-0261.12039. Epub 2017 Feb 17.
7
Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.组蛋白去乙酰化酶通过抑制肝癌细胞中的 microRNA-449 来激活肝细胞生长因子信号通路。
Gastroenterology. 2012 Sep;143(3):811-820.e15. doi: 10.1053/j.gastro.2012.05.033. Epub 2012 May 26.
8
Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway.微小RNA-30a-5p的过表达通过靶向MTDH/PTEN/AKT通路抑制肝癌细胞增殖并诱导其凋亡。
Tumour Biol. 2016 May;37(5):5885-95. doi: 10.1007/s13277-015-4456-1. Epub 2015 Nov 21.
9
Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.外泌体 microRNA-32-5p 通过 PI3K/Akt 通路诱导肝癌多药耐药。
J Exp Clin Cancer Res. 2018 Mar 12;37(1):52. doi: 10.1186/s13046-018-0677-7.
10
miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.微小RNA-494通过靶向磷脂酰肌醇-3-激酶的磷酸酶和张力蛋白同源物促进肝细胞癌的细胞增殖、迁移和侵袭,并增强对索拉非尼的耐药性。
Oncol Rep. 2015 Aug;34(2):1003-10. doi: 10.3892/or.2015.4030. Epub 2015 Jun 4.

引用本文的文献

1
Exploring the Antitumor Mechanisms of Bai-Hua-She-She-Cao and Ban-Zhi-Lian against Head and Neck Squamous Cell Carcinoma: A Study on Natural Anticancer Therapeutics.探索白花蛇舌草和半枝莲对头颈鳞状细胞癌的抗肿瘤机制:天然抗癌疗法的研究
ACS Omega. 2025 Jul 31;10(31):34528-34538. doi: 10.1021/acsomega.5c03068. eCollection 2025 Aug 12.
2
MicroRNA expression profiles in sinonasal biopsies to support diagnosis of granulomatosis with polyangiitis.鼻旁窦活检组织中的微小RNA表达谱有助于支持显微镜下多血管炎的诊断。
Front Immunol. 2025 Apr 14;16:1579750. doi: 10.3389/fimmu.2025.1579750. eCollection 2025.
3
Exploring Potential Impact of Graphene Oxide and Graphene Oxide-Polyethylenimine on Biological Behavior of Human Amniotic Fluid-Derived Stem Cells.

本文引用的文献

1
Hepatobiliary cancers, version 2.2014.肝胆癌临床实践指南(2014 年第 2 版)
J Natl Compr Canc Netw. 2014 Aug;12(8):1152-82. doi: 10.6004/jnccn.2014.0112.
2
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.Brivanib 用于索拉非尼不耐受或治疗失败的晚期肝细胞癌患者:BRISK-PS 研究的随机 III 期结果。
J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26.
3
Chemopreventive strategies in hepatocellular carcinoma.
探索氧化石墨烯及氧化石墨烯-聚乙烯亚胺对人羊水来源干细胞生物学行为的潜在影响。
Int J Mol Sci. 2024 Dec 19;25(24):13598. doi: 10.3390/ijms252413598.
4
Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance.肝细胞癌(HCC)对酪氨酸激酶抑制剂的耐药性:临床意义及克服耐药性的潜在策略
Cancers (Basel). 2024 Nov 25;16(23):3944. doi: 10.3390/cancers16233944.
5
Differential circulating miRNA profiles identified miR-423-5p, miR-93-5p, and miR-4532 as potential biomarkers for cholangiocarcinoma diagnosis.差异循环miRNA谱鉴定出miR-423-5p、miR-93-5p和miR-4532作为胆管癌诊断的潜在生物标志物。
PeerJ. 2024 Dec 10;12:e18367. doi: 10.7717/peerj.18367. eCollection 2024.
6
Non-coding RNAs as therapeutic targets in cancer and its clinical application.非编码RNA作为癌症的治疗靶点及其临床应用。
J Pharm Anal. 2024 Jul;14(7):100947. doi: 10.1016/j.jpha.2024.02.001. Epub 2024 Feb 8.
7
Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma.肝细胞癌发病机制中遗传学与生物化学之间的相互作用。
Hepatol Forum. 2024 Jul 2;5(3):150-160. doi: 10.14744/hf.2023.2023.0028. eCollection 2024.
8
Exploring non-coding RNA mechanisms in hepatocellular carcinoma: implications for therapy and prognosis.探讨肝细胞癌中非编码 RNA 机制:对治疗和预后的影响。
Front Immunol. 2024 May 10;15:1400744. doi: 10.3389/fimmu.2024.1400744. eCollection 2024.
9
The underlying mechanism and targeted therapy strategy of miRNAs cross-regulating EMT process through multiple signaling pathways in hepatocellular carcinoma.微小RNA通过多种信号通路交叉调控肝细胞癌上皮-间质转化过程的潜在机制及靶向治疗策略
Front Mol Biosci. 2024 Mar 22;11:1378386. doi: 10.3389/fmolb.2024.1378386. eCollection 2024.
10
Enhancing oral squamous cell carcinoma prediction: the prognostic power of the worst pattern of invasion and the limited impact of molecular resection margins.增强口腔鳞状细胞癌预测:侵袭最差模式的预后价值及分子切缘的有限影响
Front Oncol. 2023 Dec 22;13:1287650. doi: 10.3389/fonc.2023.1287650. eCollection 2023.
肝细胞癌的化学预防策略。
Nat Rev Gastroenterol Hepatol. 2014 Jan;11(1):45-54. doi: 10.1038/nrgastro.2013.143. Epub 2013 Aug 13.
4
miR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells.miR-148a 在肝脏中发挥关键作用,促进肝特异性表型,并抑制转化细胞的侵袭性。
Hepatology. 2013 Sep;58(3):1153-65. doi: 10.1002/hep.26422. Epub 2013 Jul 30.
5
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.HBV 和 HCV 相关肝细胞癌的发病机制。
Nat Rev Cancer. 2013 Feb;13(2):123-35. doi: 10.1038/nrc3449.
6
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.替沃扎尼(Tivantinib)二线治疗晚期肝细胞癌的随机、安慰剂对照 2 期研究。
Lancet Oncol. 2013 Jan;14(1):55-63. doi: 10.1016/S1470-2045(12)70490-4. Epub 2012 Nov 20.
7
MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?微小 RNA:在肝细胞癌的诊断、预后和治疗中有何新工具?
Hepatology. 2013 Feb;57(2):840-7. doi: 10.1002/hep.26095. Epub 2012 Dec 26.
8
Effects of AFP gene silencing on apoptosis and proliferation of a hepatocellular carcinoma cell line.甲胎蛋白基因沉默对一种肝癌细胞系凋亡及增殖的影响。
Discov Med. 2012 Aug;14(75):115-24.
9
Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells.微小 RNA-93 通过调控 PTEN/Akt 信号通路参与调节卵巢癌细胞对化疗药物顺铂的敏感性。
FEBS Lett. 2012 May 7;586(9):1279-86. doi: 10.1016/j.febslet.2012.03.006. Epub 2012 Mar 27.
10
Targeting MET in cancer: rationale and progress.靶向 MET 治疗癌症:原理与进展。
Nat Rev Cancer. 2012 Jan 24;12(2):89-103. doi: 10.1038/nrc3205.